With a strong background in specialty glass and coatings Trajan Scientific and Medical (Trajan) has introduced a new range of microscopy products.
Trajan's General Manager, Microscopy Products, Ms Angela Tomisich says that microscopy is a key technique where premium products can be brought to market to have a positive impact on patient outcomes, in line with the Trajan vision.
“By working closely with partners in pathology and healthcare, we want to continue to develop our range of products in ways that have a positive impact on the diagnostic process. In a world that is increasingly driven to drive down healthcare costs, we want to play a strong role in ensuring that patient outcomes are not compromised.” said Ms Tomisich.
Ms Tomisich is a Director on the Board of Trajan and brings a breadth of management and clinical research experience. She attained a Bachelor of Applied Science (Applied Chemistry) from RMIT, Melbourne, Australia, and Bachelor of Science (Biomedical Science) from Deakin University, Melbourne, Australia. In 2006, she was also placed on the Cornell University Dean’s List following a cell physiology and genomics program in Ithaca, USA.
Prior to Trajan, Ms Tomisich was involved the monitoring of clinical trials in Australia and New Zealand for protocols that were complex and required knowledge in advanced therapeutic areas, including oncology, cardiology, and neurology.
Ms Tomisich is also a member of the Digital Pathology Association, and has a keen interest in emerging methods and technologies to improve diagnostic practices.
For a preview of Trajan’s capabilities in microscopy products, please view the page below or contact the Trajan team directly to discuss your microscopy requirements.
Angela Tomisich, General Manager, Microscopy Products
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.